$NNVC
NANOVIRICIDES, INC. Stock $nnvc

$nnvc Overview Financials Valuation SEC Filings Company Website

2022 Q4 Form 10-K Financial Statement

#000141057822002878 Filed on October 13, 2022

Income Statement

Concept	2022 Q4	2022 Q2	2022
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$660.0K	$621.2K	$2.329M
YoY Change	0.11%	26.74%	-11.44%
% of Gross Profit
Research & Development	$1.171M	$1.172M	$5.785M
YoY Change	-7.18%	-26.04%	-5.39%
% of Gross Profit
Depreciation & Amortization	$184.9K	$188.0K	$715.1K
YoY Change	5.44%	6.69%	1.49%
% of Gross Profit
Operating Expenses	$1.834M	$1.793M	$8.114M
YoY Change	-4.51%	-13.57%	-7.21%
Operating Profit	-$1.834M		-$8.114M
YoY Change	-4.51%		-7.21%
Interest Expense	$94.00	$12.79K	$5.123K
YoY Change	-96.43%	820.14%	-106.74%
% of Operating Profit
Other Income/Expense, Net	$88.86K		$6.736K
YoY Change	-16024.73%		-108.63%
Pretax Income	-$1.745M	-$1.780M	-$8.107M
YoY Change	-9.16%	-14.13%	-8.11%
Income Tax	$0.00	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$1.745M	-$1.780M	-$8.100M
YoY Change	-9.16%	-14.13%	-8.19%
Net Earnings / Revenue
Basic Earnings Per Share	-$0.15		-$0.70
Diluted Earnings Per Share	-$0.15	-$154.0K	-$0.70
COMMON SHARES
Basic Shares Outstanding	11.59M	11.55M	11.53M
Diluted Shares Outstanding	11.61M		11.53M

Balance Sheet

Concept	2022 Q4	2022 Q2	2022
SHORT-TERM ASSETS
Cash & Short-Term Investments	$11.45M	$14.07M	$14.07M
YoY Change	-33.96%	-31.44%	-31.44%
Cash & Equivalents	$11.45M	$14.10M	$14.07M
Short-Term Investments
Other Short-Term Assets	$104.6K	$350.0K	$350.0K
YoY Change	-41.69%	13.98%	13.98%
Inventory
Prepaid Expenses	$104.5K	$350.0K
Receivables
Other Receivables
Total Short-Term Assets	$11.55M	$14.42M	$14.42M
YoY Change	-34.04%	-30.77%	-30.77%
LONG-TERM ASSETS
Property, Plant & Equipment	$8.418M	$8.694M	$8.694M
YoY Change	-5.89%	-4.3%	-4.3%
Goodwill
YoY Change
Intangibles	$337.7K	$341.8K
YoY Change	-2.39%	-2.36%
Long-Term Investments
YoY Change
Other Assets	$26.51K	$42.44K	$42.44K
YoY Change	653.13%	1105.68%	1105.68%
Total Long-Term Assets	$8.782M	$9.078M	$9.078M
YoY Change	-5.51%	-3.81%	-3.81%
TOTAL ASSETS
Total Short-Term Assets	$11.55M	$14.42M	$14.42M
Total Long-Term Assets	$8.782M	$9.078M	$9.078M
Total Assets	$20.33M	$23.49M	$23.49M
YoY Change	-24.15%	-22.36%	-22.36%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$412.7K	$272.4K	$272.4K
YoY Change	28.92%	17.62%	17.62%
Accrued Expenses	$51.88K	$45.69K	$45.69K
YoY Change	114.75%	88.15%	88.1%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$94.79K	$94.79K
YoY Change		-0.55%	-0.55%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$464.6K	$412.8K	$412.8K
YoY Change	34.94%	17.57%	17.57%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities	$0.00	$0.00	$0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities	$464.6K	$412.8K	$412.8K
Total Long-Term Liabilities	$0.00	$0.00	$0.00
Total Liabilities	$464.6K	$412.8K	$412.8K
YoY Change	34.94%	17.57%	17.57%
SHAREHOLDERS EQUITY
Retained Earnings	-$125.8M	-$122.5M
YoY Change	5.72%	7.09%
Common Stock	$11.63K	$11.59K
YoY Change	0.87%	0.67%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$19.87M	$23.08M	$23.08M
YoY Change
Total Liabilities & Shareholders Equity	$20.33M	$23.49M	$23.49M
YoY Change	-24.15%	-22.36%	-22.36%

Cashflow Statement

Concept	2022 Q4	2022 Q2	2022
OPERATING ACTIVITIES
Net Income	-$1.745M	-$1.780M	-$8.100M
YoY Change	-9.16%	-14.13%	-8.19%
Depreciation, Depletion And Amortization	$184.9K	$188.0K	$715.1K
YoY Change	5.44%	6.69%	1.49%
Cash From Operating Activities	-$1.401M	-$1.398M	-$5.900M
YoY Change	-33.76%	-37.26%	-28.17%
INVESTING ACTIVITIES
Capital Expenditures	$45.34K	-$75.36K	$324.3K
YoY Change	-124.46%	-10.96%	-235.85%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	-$45.34K	-$75.36K	-$324.4K
YoY Change	-75.54%	-10.96%	35.85%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-23.84K	-32.71K	-234.7K
YoY Change	-61.15%	-53.6%	-101.54%
NET CHANGE
Cash From Operating Activities	-1.401M	-1.398M	-5.900M
Cash From Investing Activities	-45.34K	-75.36K	-324.4K
Cash From Financing Activities	-23.84K	-32.71K	-234.7K
Net Change In Cash	-1.470M	-1.506M	-6.135M
YoY Change	-37.75%	-36.81%	-190.11%
FREE CASH FLOW
Cash From Operating Activities	-$1.401M	-$1.398M	-$5.900M
Capital Expenditures	$45.34K	-$75.36K	$324.3K
Free Cash Flow	-$1.446M	-$1.322M	-$6.224M
YoY Change	-25.04%	-38.3%	-21.95%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
CY2022	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2022	dei	Entity Address City Or Town EntityAddressCityOrTown	SHELTON
CY2022Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2021Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2022	dei	Entity Central Index Key EntityCentralIndexKey	0001379006
CY2022	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--06-30
CY2022	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
CY2022	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2022	dei	Amendment Flag AmendmentFlag	false
CY2022	dei	Trading Symbol TradingSymbol	NNVC
CY2022	dei	Document Transition Report DocumentTransitionReport	false
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	11534698
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	10900955
CY2022	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	NV
CY2022	dei	Entity Address State Or Province EntityAddressStateOrProvince	CT
CY2022Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	11592173
CY2021Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	11515170
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.70
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.81
CY2022	dei	Document Type DocumentType	10-K
CY2022	dei	Document Annual Report DocumentAnnualReport	true
CY2022	dei	Document Period End Date DocumentPeriodEndDate	2022-06-30
CY2022	dei	Entity File Number EntityFileNumber	001-36081
CY2022	dei	Entity Registrant Name EntityRegistrantName	NANOVIRICIDES, INC.
CY2022	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	76-0674577
CY2022	dei	Entity Address Address Line1 EntityAddressAddressLine1	1 CONTROLS DRIVE
CY2022	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	06484
CY2022	dei	City Area Code CityAreaCode	203
CY2022	dei	Local Phone Number LocalPhoneNumber	937-6137
CY2022	dei	Security12b Title Security12bTitle	COMMON STOCK, PAR VALUE $0.001 PER SHARE
CY2022	dei	Security Exchange Name SecurityExchangeName	NYSE
CY2022	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2022	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2022	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2022	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2022	dei	Entity Small Business EntitySmallBusiness	true
CY2022	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2022	dei	Entity Shell Company EntityShellCompany	false
CY2022Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	11592000
CY2021Q4	dei	Entity Public Float EntityPublicFloat	40756000
CY2022	dei	Auditor Firm AuditorFirmId	274
CY2022	dei	Auditor Name AuditorName	EISNERAMPER LLP
CY2022	dei	Auditor Location AuditorLocation	Iselin, New Jersey
CY2022Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	14066359
CY2021Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	20516677
CY2022Q2	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	350021
CY2021Q2	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	307102
CY2022Q2	us-gaap	Assets Current AssetsCurrent	14416380
CY2021Q2	us-gaap	Assets Current AssetsCurrent	20823779
CY2022Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	14658014
CY2021Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	14333666
CY2022Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	5963820
CY2021Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	5248765
CY2022Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	8694194
CY2021Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	9084901
CY2022Q2	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	458954
CY2021Q2	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	458954
CY2022Q2	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	117106
CY2021Q2	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	108836
CY2022Q2	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	341848
CY2021Q2	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	350118
CY2022Q2	us-gaap	Security Deposit SecurityDeposit	3515
CY2021Q2	us-gaap	Security Deposit SecurityDeposit	3515
CY2022Q2	nnvc	Service Agreements ServiceAgreements	38925
CY2021Q2	nnvc	Service Agreements ServiceAgreements	0
CY2022Q2	us-gaap	Other Assets OtherAssets	42440
CY2021Q2	us-gaap	Other Assets OtherAssets	3515
CY2022Q2	us-gaap	Assets Assets	23494862
CY2021Q2	us-gaap	Assets Assets	30262313
CY2022Q2	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	57960
CY2021Q2	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	200016
CY2022Q2	us-gaap	Accounts Payable Related Parties Current AccountsPayableRelatedPartiesCurrent	214397
CY2021Q2	us-gaap	Accounts Payable Related Parties Current AccountsPayableRelatedPartiesCurrent	31539
CY2022Q2	us-gaap	Loans Payable LoansPayable	94788
CY2021Q2	us-gaap	Loans Payable LoansPayable	95306
CY2022Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	45692
CY2021Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	24285
CY2022Q2	us-gaap	Liabilities Current LiabilitiesCurrent	412837
CY2021Q2	us-gaap	Liabilities Current LiabilitiesCurrent	351146
CY2021Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2021Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000
CY2022Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000
CY2022Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	11592173
CY2021Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	11515170
CY2022Q2	us-gaap	Common Stock Value CommonStockValue	11592
CY2021Q2	us-gaap	Common Stock Value CommonStockValue	11515
CY2022Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	145562124
CY2021Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	144284593
CY2022Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-122492176
CY2021Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-114385313
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	23082025
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	29911167
CY2022Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	23494862
CY2021Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	30262313
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	5784862
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	6114541
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2328737
CY2021	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2629565
CY2022	us-gaap	Operating Expenses OperatingExpenses	8113599
CY2021	us-gaap	Operating Expenses OperatingExpenses	8744106
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-8113599
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-8744106
CY2022	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	11859
CY2021	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	9348
CY2022	us-gaap	Interest Expense InterestExpense	5123
CY2021	us-gaap	Interest Expense InterestExpense	85405
CY2021	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-2026
CY2022	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	6736
CY2021	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-78083
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-8106863
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-8822189
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-8106863
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-8822189
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.70
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.81
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	11534698
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	10900955
CY2020Q2	us-gaap	Stockholders Equity StockholdersEquity	21757962
CY2021	nnvc	Series Preferred Shares Issued During Period Employee Stock Compensation Value Issued SeriesPreferredSharesIssuedDuringPeriodEmployeeStockCompensationValueIssued	226306
CY2021	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	16563697
CY2021	nnvc	Stock Issued During July Value Issued For Share Based Compensation Consulting And Legal Service One StockIssuedDuringJulyValueIssuedForShareBasedCompensationConsultingAndLegalServiceOne	108000
CY2021	nnvc	Stock Issued During Shares Issued For Share Based Compensation Consulting And Legal Services StockIssuedDuringSharesIssuedForShareBasedCompensationConsultingAndLegalServices	6103
CY2021	us-gaap	Stock Issued During Period Value Employee Benefit Plan StockIssuedDuringPeriodValueEmployeeBenefitPlan	15038
CY2021	nnvc	Stock Issued For Payment Of Director Fees Value StockIssuedForPaymentOfDirectorFeesValue	56250
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-8822189
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	29911167
CY2022	nnvc	Series Preferred Shares Issued During Period Employee Stock Compensation Value Issued SeriesPreferredSharesIssuedDuringPeriodEmployeeStockCompensationValueIssued	135400
CY2022	nnvc	Series Preferred Shares Value Issued During Period For License Agreement SeriesPreferredSharesValueIssuedDuringPeriodForLicenseAgreement	935088
CY2022	nnvc	Stock Issued During July Value Issued For Share Based Compensation Consulting And Legal Service One StockIssuedDuringJulyValueIssuedForShareBasedCompensationConsultingAndLegalServiceOne	108000
CY2022	nnvc	Stock Issued During Shares Issued For Share Based Compensation Consulting And Legal Services StockIssuedDuringSharesIssuedForShareBasedCompensationConsultingAndLegalServices	4215
CY2022	us-gaap	Stock Issued During Period Value Employee Benefit Plan StockIssuedDuringPeriodValueEmployeeBenefitPlan	6768
CY2022	nnvc	Stock Issued For Payment Of Director Fees Value StockIssuedForPaymentOfDirectorFeesValue	52500
CY2022	nnvc	Common Stock Value Issued For Professional Service CommonStockValueIssuedForProfessionalService	35750
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-8106863
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	23082025
CY2022	us-gaap	Profit Loss ProfitLoss	-8106863
CY2021	us-gaap	Profit Loss ProfitLoss	-8822189
CY2022	nnvc	Preferred Shares Issued As Compensation PreferredSharesIssuedAsCompensation	135400
CY2021	nnvc	Preferred Shares Issued As Compensation PreferredSharesIssuedAsCompensation	226306
CY2022	nnvc	Preferred Shares Issued For License Agreement PreferredSharesIssuedForLicenseAgreement	935088
CY2021	nnvc	Preferred Shares Issued For License Agreement PreferredSharesIssuedForLicenseAgreement	0
CY2022	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	203018
CY2021	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	179288
CY2022	us-gaap	Adjustment Of Warrants Granted For Services AdjustmentOfWarrantsGrantedForServices	4215
CY2021	us-gaap	Adjustment Of Warrants Granted For Services AdjustmentOfWarrantsGrantedForServices	6103
CY2022	us-gaap	Depreciation Depreciation	715055
CY2021	us-gaap	Depreciation Depreciation	696268
CY2022	nnvc	Amortization Of Loan Origination Fees AmortizationOfLoanOriginationFees	0
CY2021	nnvc	Amortization Of Loan Origination Fees AmortizationOfLoanOriginationFees	18013
CY2022	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	8270
CY2021	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	8270
CY2022	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	0
CY2021	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-2026
CY2022	nnvc	Written Off Financing Costs Classified As Operating Activities WrittenOffFinancingCostsClassifiedAsOperatingActivities	0
CY2021	nnvc	Written Off Financing Costs Classified As Operating Activities WrittenOffFinancingCostsClassifiedAsOperatingActivities	12190
CY2022	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-191279
CY2021	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-205436
CY2022	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	38925
CY2021	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-10158
CY2022	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	-142056
CY2021	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	-180711
CY2022	us-gaap	Increase Decrease In Accounts Payable Related Parties IncreaseDecreaseInAccountsPayableRelatedParties	182858
CY2021	us-gaap	Increase Decrease In Accounts Payable Related Parties IncreaseDecreaseInAccountsPayableRelatedParties	-530041
CY2022	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	21407
CY2021	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	-44953
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-5891254
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-8213836
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	324348
CY2021	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	238765
CY2022	nnvc	Proceeds From Issuance Of Common Stock And Warrants ProceedsFromIssuanceOfCommonStockAndWarrants	0
CY2021	nnvc	Proceeds From Issuance Of Common Stock And Warrants ProceedsFromIssuanceOfCommonStockAndWarrants	16563697
CY2022	nnvc	Payment Of Note Payable Related Party PaymentOfNotePayableRelatedParty	0
CY2021	nnvc	Payment Of Note Payable Related Party PaymentOfNotePayableRelatedParty	1100000
CY2022	nnvc	Payment Of Loans Payable PaymentOfLoansPayable	234716
CY2021	nnvc	Payment Of Loans Payable PaymentOfLoansPayable	203013
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-234716
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	15260684
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-6450318
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	6808083
CY2021Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	20516677
CY2020Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	13708594
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	14066359
CY2021Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	20516677
CY2022	us-gaap	Interest Paid Net InterestPaidNet	5123
CY2021	us-gaap	Interest Paid Net InterestPaidNet	4858
CY2022	us-gaap	Income Taxes Paid IncomeTaxesPaid	0
CY2021	us-gaap	Income Taxes Paid IncomeTaxesPaid	0
CY2022	nnvc	Directors And Officers Insurance Financed Through Loan DirectorsAndOfficersInsuranceFinancedThroughLoan	234198
CY2021	nnvc	Directors And Officers Insurance Financed Through Loan DirectorsAndOfficersInsuranceFinancedThroughLoan	235476
CY2022	us-gaap	Nature Of Operations NatureOfOperations	<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Note 1 – Organization and Nature of Business</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">NanoViricides, Inc. (the “Company”) is a nano-biopharmaceutical research and development company specializing in the discovery, development, and commercialization of drugs to combat viral infections using its unique and novel nanomedicines technology. NanoViricides is also unique in the bio-pharma field in that it possesses its own state of the art facilities for the design, synthesis, analysis and characterization of the nanomedicines that we develop, as well as for production scale-up, and c-GMP-like production in quantities needed for human clinical trials, where our design, development, and production work is performed. The biological studies such as the effectiveness, safety, bio-distribution and Pharmacokinetics/Pharmacodynamics on our drug candidates are performed by external collaborators and contract organizations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">The Company has several drugs in various stages of early development. COVID-19 has become our lead drug program due to the necessity of responding to the pandemic. The Company has a clinical lead candidate NV-CoV-2 for the treatment of SARS-CoV-2 infection (COVID-19 disease) that has shown excellent effectiveness and safety in pre-clinical studies. IND-enabling studies of NV-CoV-2 have been completed. The Company is working on IND writing and engaging a Clinical Trials Clinical Research Organization in pursuit of Phase I/II human clinical trials of this drug. The Company is also working on performing clinical trials of this drug outside the USA. The Company began development of a drug to treat COVID-19 patients just as the cases of the novel disease were being reported from China. The Company cannot provide a timeline at this point because of external dependencies in the filing of regulatory applications, their approval(s) and beginning of clinical trials. As of June 30, 2022, there is only one antiviral drug (remdesivir) approved, and two non-antibody antiviral drugs (Paxlovid, Pfizer and Molnupiravir, Merck) given Emergency Use Authorization (EUA) by the FDA. Several of previously approved antibody therapies have lost efficacy and their EUAs have been revoked, as the virus mutated and new variants came in the field, as previously predicted by the Company. The antibodies that remain under EUA are expected to lose effectiveness as the virus continues to mutate and new escape variants take over. All of these drug approvals are restricted to specific population subsets, and there is no drug that is generally approved for treatment of COVID-19, particularly for patients with no co-morbidities and not at risk of hospitalization (https://www.fda.gov/drugs/emergency-preparedness-drugs/coronavirus-covid-19-drugs). In addition, there are at least three vaccines licensed in the USA and several more are in use internationally. Internationally, virus variants have continued to emerge with resistance to drugs and vaccines. Scientists believe it is only a matter of time before escape variants against existing antibodies and vaccines, including the newly introduced Omicron/Original Strain bi-valent vaccines, and therapeutics become commonplace. Thus there is an unmet need that the Company’s broad-spectrum, pan-coronavirus drug NV-CoV-2 is expected to fulfill for therapeutics that the virus would not escape by mutations. Additionally, specific populations such as immune-compromised persons, HIV-positive persons, and others would require therapeutics even if they are fully vaccinated, as the weak immune system in these populations limits the ability of vaccines to protect from COVID-19 infection and disease. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">In response to the recent Monkeypox virus (MPXV) epidemic, the Company has begun a limited drug development program to treat MPXV patients. At present, while it appears that this epidemic is quieting down, experts expect that this virus will become endemic in the Western world, as it is in the African subcontinent (https://www.cdc.gov/poxvirus/monkeypox/cases-data/technical-report/report-3.html#dynamics). A vaccine against smallpox appears to have substantial effectiveness in protecting vaccinated persons from MPXV infection. The only currently available drug, tecovirimat, approved for smallpox, has a low escape barrier for virus mutations, and has other limitations on its use. Thus there remains an urgent need for broad-spectrum drugs that can treat MPXV, smallpox, and other poxviruses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">Additionally, in response to the ongoing pediatric “acute flaccid myelitis” (AFM, a disease that can lead to paralysis) cases that appear to be on an uptick, the Company has initiated a limited broad-spectrum drug development program for the treatment of Enterovirus D68 (EV68), the cause of AFM, and potentially other enteroviruses including the poliovirus. Cases of polio have begun to emerge in the United States. Apparently due to loss of “herd immunity” as the poliovirus immunizations in childhood have dropped, the cases are caused by what is believed to a be a revertant of the attenuated strain of poliovirus that is used for vaccination in certain underdeveloped countries.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">The Company intends to run both MPXV and EVD68 programs by initially evaluating the Company’s existing drug candidate library for effectiveness. If effective existing drug candidates are found, the Company intends to undertake additional work as well as seek additional financing, preferably via non-dilutive funding sources.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">The Company plans on re-engaging our other lead antiviral program against herpes viruses, i.e. the HerpeCide<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">™</sup> program, as soon as it becomes feasible to conduct the corresponding antiviral human clinical studies. In the HerpeCide program alone, the Company has drug candidates against at least five indications at different stages of development. Of these, the Company is advancing the shingles drug candidate towards human clinical trials. The IND-enabling Safety/Toxicology studies required for doing so have been completed and the Company was in the process of preparing an IND application for this drug candidate when the SRAS-CoV-2 virus struck, whereupon we pivoted our efforts to respond to the threat of what has now become the COVID-19 pandemic. In addition, the Company’s drug candidates against HSV-1 “cold sores” and HSV-2 “genital herpes” are in advanced studies and are expected to follow the shingles drug candidate into human clinical trials. Shingles in adults and chicken pox in children is caused by the same virus, namely VZV (Varicella-zoster virus, aka HHV-3 or human herpesvirus-3). There are estimated to be approximately 120,000-150,000 annual chickenpox cases in the USA in the post-vaccination-era, i.e. since childhood vaccination with the live attenuated varicella virus Oka strain has become standard. In addition, the Company has drugs in development against all influenzas in our FluCide<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">™</sup> program, as well as drug candidates against HIV/AIDS, Dengue, Ebola/Marburg, and other viruses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:0pt;margin:0pt;">The Company’s drugs are based on several patents, patent applications, provisional patent applications, and other proprietary intellectual property held by TheraCour Pharma, Inc. (“TheraCour”), to which the Company has broad, exclusive licenses. The first license agreement the Company executed with TheraCour on September 1, 2005 (“Exclusive License Agreement”), gave the Company an exclusive, worldwide license for the treatment of the following human viral diseases: Human Immunodeficiency Virus (HIV/AIDS), Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), Herpes Simplex Virus (HSV), Influenza and Asian Bird Flu Virus. On February 15, 2010, the Company executed an Additional Agreement (“Additional License Agreement”) with TheraCour. Pursuant to the Additional License Agreement, the Company was granted exclusive licenses for technologies, developed by TheraCour, for the development of drug candidates for the treatment of Dengue viruses, Ebola/Marburg viruses, Japanese Encephalitis, viruses causing viral Conjunctivitis (a disease of the eye) and Ocular Herpes. In addition, on November 1, 2019, the Company entered into a world-wide, exclusive, sub-licensable, license (“VZV License Agreement”) to use, promote, offer for sale, import, export, sell and distribute drugs that treat VZV infections, using TheraCour’s proprietary as well as patented technology and intellectual property. The discovery of ligands and polymer materials as well as formulations, the chemistry and chemical characterization, as well as process development and related work will be performed by TheraCour under the same compensation terms as prior agreements between the parties, with no duplication of costs allowed. Upon commercialization, NanoViricides will pay 15% of net sales to TheraCour, as defined in the agreement. The Company was not required to make any upfront payments to TheraCour and agreed to the following milestone payments to TheraCour; the issuance of 75,000 shares of the Company’s Series A preferred stock upon the grant of an IND Application; $1,500,000 in cash upon completion of Phase I Clinical Trials; $2,500,000 in cash upon completion of Phase II clinical trials; and $5,000,000 in cash upon completion of Phase III clinical trials.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;"></span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:0pt;margin:0pt;">On September 9, 2021, the Company entered into a world-wide, exclusive, sub-licensable, license (“Covid-19 License Agreement”) to use, promote, offer for sale, import, export, sell and distribute drugs that treat COVID-19 infections, using TheraCour’s proprietary as well as patented technology and intellectual property. The discovery of ligands and polymer materials as well as formulations, the chemistry and chemical characterization, as well as process development and related work will be performed by TheraCour under the same compensation terms as prior agreements between the parties, with no duplication of costs allowed. Upon commercialization, NanoViricides will pay 15% of net sales to TheraCour, as defined in the agreement. The Company was not required to make any upfront cash payments to TheraCour and agreed to the following milestone payments to TheraCour: (i) the issuance of 100,000 shares of the Company’s Series A preferred stock within 30 days upon execution of this agreement; (ii) the issuance of 50,000 shares of the Company’s Series A preferred stock upon the approval of the Company’s IND Application or its equivalent by a competent regulatory authority; (iii) $1,500,000 upon initiation of Phase I clinical trials, or its equivalent, for at least one licensed product within-the field on, or before, three (3) months from the date of the authority’s acceptance of the IND, or its equivalent; (iv) $2,000,000 in cash upon completion of Phase 1 clinical trials; (v) $2,500,000 in cash upon completion of Phase IIA clinical trials, or, its equivalent; (vi) the issuance of 100,000 shares of the Company’s Series A preferred stock upon the initiation of Phase 3 clinical trials, or, its equivalent, for at least one licensed product within the field; and (vii) $5,000,000 in cash, or 500,000 shares of the Company’s Series A preferred stock upon completion of Phase III clinical trials, or its equivalent. Upon commercialization, NanoViricides will pay 15% of net sales to TheraCour, as defined in the agreement. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;"></span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:0pt;margin:0pt;">At present the Company does not hold a license for monkeypox therapeutics. As with the Company’s standard policy, if the exploratory work commissioned by the Company leads to potentially effective candidates, and if the Company chooses to further engage in commercial development of the same, then the Company will perform the activities required to obtain such a license. TheraCour has not denied any licenses to NanoViricides to date. </p>
CY2019Q4	nnvc	Stock Issued During Period Value New Issues Cash Upon Completion Of Phase1 Clinical Trials StockIssuedDuringPeriodValueNewIssuesCashUponCompletionOfPhase1ClinicalTrials	1500000
CY2019Q4	nnvc	Stock Issued During Period Value New Issues Cash Upon Completion Of Phase2 Clinical Trials StockIssuedDuringPeriodValueNewIssuesCashUponCompletionOfPhase2ClinicalTrials	2500000
CY2019Q4	nnvc	Stock Issued During Period Value New Issues Cash Upon Completion Of Phase3 Clinical Trials StockIssuedDuringPeriodValueNewIssuesCashUponCompletionOfPhase3ClinicalTrials	5000000
CY2022Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-122500000
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-8100000
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-5900000
CY2022Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	14100000
CY2022	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	9146
CY2021	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	14416
CY2022Q2	us-gaap	Land Land	260000
CY2021Q2	us-gaap	Land Land	260000
CY2022Q2	nnvc	Office Equipment Gross OfficeEquipmentGross	57781
CY2022	us-gaap	Use Of Estimates UseOfEstimates	<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><i style="text-decoration-line:underline;text-decoration-style:solid;">Use of Estimates</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. The Company bases its estimates on historical experience and on various assumptions that are believed to be reasonable under the circumstances. The amounts of assets and liabilities reported in the Company’s balance sheet and the amounts of expenses reported for each of the periods presented are affected by estimates and assumptions, which are used for but not limited to, accounting for share-based compensation and accounting for income taxes. Actual results could differ from those estimates.</p>
CY2021Q2	nnvc	Office Equipment Gross OfficeEquipmentGross	57781
CY2022Q2	us-gaap	Furniture And Fixtures Gross FurnitureAndFixturesGross	5607
CY2021Q2	us-gaap	Furniture And Fixtures Gross FurnitureAndFixturesGross	5607
CY2022Q2	us-gaap	Fixtures And Equipment Gross FixturesAndEquipmentGross	6185210
CY2021Q2	us-gaap	Fixtures And Equipment Gross FixturesAndEquipmentGross	5989807
CY2022Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	14658014
CY2021Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	14333666
CY2022Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	5963820
CY2021Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	5248765
CY2021Q2	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0
CY2022Q2	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0
CY2022	us-gaap	Unrecognized Tax Benefits Interest On Income Taxes Expense UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense	1258
CY2021	us-gaap	Unrecognized Tax Benefits Interest On Income Taxes Expense UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense	0
CY2022	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><i style="text-decoration-line:underline;text-decoration-style:solid;">Concentrations of Risk</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">Financial instruments that potentially subject us to a significant concentration of credit risk consist primarily of cash and cash equivalents. The Company maintains deposits in FDIC or SIPC insured institutions in excess of federally insured limits under the FDIC. The Company does not believe it is exposed to significant credit risk due to the financial position of the depository institutions in which those deposits are held.</p>
CY2022Q2	nnvc	Debt Instrument Interest Payable Escrowed DebtInstrumentInterestPayableEscrowed	132000
CY2022	nnvc	Interest Expense Which Reduced Interest Escrow Deposit Retained By Lender Amount InterestExpenseWhichReducedInterestEscrowDepositRetainedByLenderAmount	0
CY2021	nnvc	Interest Expense Which Reduced Interest Escrow Deposit Retained By Lender Amount InterestExpenseWhichReducedInterestEscrowDepositRetainedByLenderAmount	62773
CY2022	nnvc	Interest Expense Which Reduced Interest Escrow Deposit Included In Prepaid Expenses InterestExpenseWhichReducedInterestEscrowDepositIncludedInPrepaidExpenses	0
CY2022Q2	us-gaap	Leasehold Improvements Gross LeaseholdImprovementsGross	8149416
CY2021Q2	us-gaap	Leasehold Improvements Gross LeaseholdImprovementsGross	8020471
CY2022Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	8694194
CY2021Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	9084901
CY2022	us-gaap	Depreciation Depreciation	715055
CY2021	us-gaap	Depreciation Depreciation	696268
CY2022Q2	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	458954
CY2021Q2	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	458954
CY2022Q2	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	117106
CY2021Q2	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	108836
CY2022Q2	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	341848
CY2021Q2	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	350118
CY2022Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	8271
CY2022Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	8271
CY2022Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	8271
CY2022Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	8271
CY2022Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	8271
CY2022Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense After Year Five FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive	300493
CY2022Q2	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	341848
CY2022Q2	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	38676
CY2021Q2	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	24285
CY2022Q2	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	7016
CY2021Q2	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	0
CY2022Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	45692
CY2021Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	24285
CY2022Q1	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	234198
CY2021Q1	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	235476
CY2022Q1	us-gaap	Debt Instrument Periodic Payment DebtInstrumentPeriodicPayment	23932
CY2021Q1	us-gaap	Debt Instrument Periodic Payment DebtInstrumentPeriodicPayment	24062
CY2022Q1	us-gaap	Debt Instrument Interest Rate Stated Percentage DebtInstrumentInterestRateStatedPercentage	0.0474
CY2021Q1	us-gaap	Debt Instrument Interest Rate Stated Percentage DebtInstrumentInterestRateStatedPercentage	0.0474
CY2022Q2	us-gaap	Loans Payable LoansPayable	94788
CY2021Q2	us-gaap	Loans Payable LoansPayable	95306
CY2022	us-gaap	Interest Expense Debt InterestExpenseDebt	5123
CY2021	us-gaap	Interest Expense Debt InterestExpenseDebt	4858
CY2020Q3	nnvc	Gross Proceeds Offering GrossProceedsOffering	11499997
CY2020Q3	nnvc	Offering Costs OfferingCosts	1057781
CY2020Q3	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	10442216
CY2021Q1	nnvc	Gross Proceeds Offering GrossProceedsOffering	6374211
CY2021Q1	nnvc	Offering Costs OfferingCosts	252730
CY2021Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	6121481
CY2022Q2	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	0
CY2022	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	0
CY2021	nnvc	Percentage Of Us Federal Income Tax Rate PercentageOfUsFederalIncomeTaxRate	0.21
CY2020	nnvc	Percentage Of Us Federal Income Tax Rate PercentageOfUsFederalIncomeTaxRate	0.21
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.2100
CY2021	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.2100
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	0.0890
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	0.0062
CY2022	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	-0.0593
CY2021	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	-0.0593
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Percent EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent	0
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Percent EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent	0
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0.0273
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0.1530
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0.2631
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0
CY2021	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0
CY2022Q2	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	27127620
CY2021Q2	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	26676579
CY2022Q2	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	7774567
CY2021Q2	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	7053228
CY2022Q2	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	1604592
CY2021Q2	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	1536892
CY2022Q2	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	36506779
CY2021Q2	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	35266699
CY2022Q2	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	36506779
CY2021Q2	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	35266699
CY2022Q2	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0
CY2021Q2	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0
CY2022Q2	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	36506779
CY2021Q2	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	35266699
CY2021	nnvc	Operating Loss That Can Be Carried Forward Indefinitely OperatingLossThatCanBeCarriedForwardIndefinitely	16100000
CY2022	nnvc	Operating Loss That Can Be Carried Forward Indefinitely OperatingLossThatCanBeCarriedForwardIndefinitely	16100000
CY2018Q1	nnvc	Net Operating Losses Incurred In Income Tax Payable Net NetOperatingLossesIncurredInIncomeTaxPayableNet	0.80
CY2022	nnvc	Employment Agreement Term EmploymentAgreementTerm	P3Y

Files In Submission

Name	View Source	Status
0001410578-22-002878-index-headers.html	Edgar Link	pending
0001410578-22-002878-index.html	Edgar Link	pending
0001410578-22-002878.txt	Edgar Link	pending
0001410578-22-002878-xbrl.zip	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
nnvc-20220630.xsd	Edgar Link	pending
nnvc-20220630x10k.htm	Edgar Link	pending
nnvc-20220630xex31d1.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
nnvc-20220630x10k_htm.xml	Edgar Link	completed
nnvc-20220630xex31d2.htm	Edgar Link	pending
nnvc-20220630xex32d1.htm	Edgar Link	pending
nnvc-20220630xex32d2.htm	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
nnvc-20220630_def.xml	Edgar Link	unprocessable
nnvc-20220630_lab.xml	Edgar Link	unprocessable
nnvc-20220630_pre.xml	Edgar Link	unprocessable
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
nnvc-20220630_cal.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$NNVC
NANOVIRICIDES, INC. Stock $nnvc

2022 Q4 Form 10-K Financial Statement

#000141057822002878 Filed on October 13, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$NNVC NANOVIRICIDES, INC. Stock $nnvc

2022 Q4 Form 10-K Financial Statement

#000141057822002878 Filed on October 13, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$NNVC
NANOVIRICIDES, INC. Stock $nnvc